Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIRCUS phase I trial of E7820 in Japanese patients with unresectable solid tumors
jRCT2031240210Phase 1Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jul 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of e7820 in Nonhematologic neoplasms, biliary cancer and endometrial cancer (EC) (5 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Incidence of dose-limiting toxicity. Started Jul 2024; status: active, not recruiting.
02
Drugs
e7820
03
Conditions
Nonhematologic neoplasmsbiliary cancerendometrial cancer (EC)
Beyond the preview
Go deeper on jRCT2031240210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240210.